tirzepatide trade name (ZEPBOUND) Approved for Chronic Weight Management in Adults with Obesity ✨ The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 kg/ m2 or In adults with obesity but

Hiu qu lu di: Cc vin ung trng da ca c c nh gi cao v hiu qu trng sng da, kh nng lm m cc vt thm sm, tn nhang t su bn trong m khng gy bo mn, kch ng da t bn ngoi

Key considerations: May reduce gastrointestinal side effects Potentially lowers treatment costs Can be useful for maintenance after significant weight loss Encourages focus on lifestyle habits rather than medication alone However: Evidence remains limited Not everyone responds the same way Lower doses may not produce adequate appetite control for many patients Dosing decisions should always be individualized and physician-guided At Metabolic, weve observed that the most successful outcomes rarely come from medication alone

& Laskin, D

Fiber feeds beneficial gut bacteria